Recent News

• 01.08.2026 - Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare Conference
• 01.05.2026 - Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
• 12.09.2025 - Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
• 12.03.2025 - Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
• 11.28.2025 - Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
• 11.18.2025 - Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
• 11.10.2025 - Oculis Reports Q3 2025 Financial Results and Provides Company Update
• 11.06.2025 - Q3-2025 Earnings Release
• 11.06.2025 - Q3-2025 Earnings Release
• 11.05.2025 - Oculis to Participate in Upcoming November Investor Conferences

Recent Filings

• 12.08.2025 - EFFECT Notice of Effectiveness
• 12.05.2025 - POS AM Post-Effective amendments for registration statement
• 12.01.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.10.2025 - EX-99.1 EX-99.1
• 11.10.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.10.2025 - F-3 Registration statement by foreign private issuers
• 10.31.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 10.31.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 10.31.2025 - EX-99.1 EX-99.1